EGFR T263P

CI-VAR-00004299Explore in graph →NP_005219.2:p.Thr263ProNM_005228.4:c.787A>CClinVar 376208 CIViC 995

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
High-Grade Glioma, NOS1
EGFR T263P	Erlotinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID4187 In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assesse… (full text at CIViC) PMID 17177598 · Lee et al., 2006 · Open in CIViC	civic
Unmapped disease1unmapped disease
EGFR T263P	(functional)	Functional	D	Supports Gain Of Function	4	submitted	EID10068 In an in vitro study, EGFR ectodomain missense mutants (T263P, A289V, G598V, L861Q) were expressed in human immortalized astrocytes and BaF3 cells. Phosphorylation was measured via immunoblot. All ect… (full text at CIViC) PMID 17177598 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.